Product Description
Arformoterol inhalation is used to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary disease (COPD; a group of lung diseases, which includes chronic bronchitis and emphysema). Arformoterol is in a class of medications called long-acting beta agonists (LABAs). It works by relaxing and opening air passages in the lungs, making it easier to breathe. (Sourced from: https://medlineplus.gov/druginfo/meds/a607061.html)
Mechanisms of Action: ADRB2 Agonist,LAB Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Bangladesh | India | Turkey | United States
Approved Indications: Asthma | Bronchitis | Bronchitis, Chronic | Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema
Known Adverse Events: Back Pain | Chest Pain | Pain Unspecified | Sinusitis | Dyspnea | Diarrhea | Edema
Company: Changtai Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Chronic Obstructive Pulmonary Disease
Phase 1: Asthma|Bronchitis, Chronic|Dyspnea|Emphysema|Kidney Diseases|Lung Diseases, Obstructive
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20211924 | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
None |
|
| CTR20210048 | P1 |
Not yet recruiting |
Bronchitis, Chronic|Kidney Diseases|Emphysema|Dyspnea|Asthma|Lung Diseases, Obstructive |
None |
|
| CTR20222650 | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
None |